Viewing data from:

POLYMYXIN B SULFATE

ANDA

POLYMYXIN B SULFATE | A060716 | HIKMA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Polymyxin B Sulfate (2023)

Total Spending

$43K

Total Claims

288

Beneficiaries

Avg Cost/Unit

$1.87

Spending Trend

$114K(2019)→$102K(2020)→$79K(2021)→$50K(2022)→$43K(2023)

YoY Change:+387.9%

5yr CAGR:+72.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain12 active DMFs2 inactive

12 active API suppliers hold Drug Master Files for this ingredient.

XELLIA PHARMACEUTICALS APSPOLYMYXIN B SULFATE

DMF 141871999

HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTDPOLYMYXIN B SULFATE

DMF 220302008

BIOTIKA ASPOLYMYXIN B SULFATE

DMF 238762010

ALP PHARM BEIJING CO LTDPOLYMYXIN B SULFATE USP

DMF 239972010

YANCHENG YOUHUA PHARMACEUTICAL AND CHEMICAL TECHNOLOGY CO LTDPOLYMYXIN B SULFATE USP

DMF 286162014

SHANDONG LUXI PHARMACEUTICAL CO LTDPOLYMYXIN B SULFATE

DMF 315872017

JIANGXI NUCLEAR INDUSTRY REYPHON BIO-CHEMICAL CO LTDPOLYMYXIN B SULFATE

DMF 316832017

NORTH CHINA PHARMACEUTICAL HUASHENG CO LTDPOLYMYXIN B SULFATE USP

DMF 358922021

LIVZON GROUP FUZHOU FUXING PHARMACEUTICAL CO LTDPOLYMYXIN B SULFATE

DMF 380192023

GANZHOU RUIZHI PHARMACEUTICAL CO LTDPOLYMYXIN B SULFATE USP

DMF 382672023

CHENGDU YACHT BIOTECHNOLOGY CO LTDPOLYMYXIN B SULFATE

DMF 413102025

HEBEI SHENGXUE DACHENG PHARMACEUTICAL CO LTDPOLYMYXIN B SULFATE

DMF 426362025

CULTOR FOOD SCIENCE INCInactivePOLYMYXIN B SULFATE

DMF 131991998

WORLD JIANGSU INDUSTRY CO LTDInactivePolymyxin B Sulfate USP (Non-Sterile Drug Substance)

DMF 212442008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 500,000 UNITS BASE/VIAL

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.